Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker INFU
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | Carrie Lachance President and CEO, Director | INFU InfuSystems Holdings, Inc. | Buy | 1,000 | $8.46 | $8,460 Buy | Form 4 ↗ |
| May 8, 2026 | Paul Andrew Gendron Director | INFU InfuSystems Holdings, Inc. | Buy | 5,000 | $8.88 | $44.4K Buy | Form 4 ↗ |
| May 8, 2026 | Carrie Lachance President and CEO, Director | INFU InfuSystems Holdings, Inc. | Buy | 2,000 | $8.83 | $17.7K Buy | Form 4 ↗ |
| May 8, 2026 | Barry G. Steele Executive VP and CFO | INFU InfuSystems Holdings, Inc. | Buy | 7,000 | $8.71 | $61.0K Buy | Form 4 ↗ |
| Mar 2, 2026 | Barry G. Steele Executive VP and CFO | INFU InfuSystems Holdings, Inc. | Buy | 2,064 | $9.16 | $18.9K Buy | Form 4 ↗ |
| Aug 22, 2025 | Scott Shuda Director | INFU InfuSystems Holdings, Inc. | Sale | 5,752 | $9.67 | $55.6K Sale | Form 4 ↗ |
| May 28, 2025 | Kenneth D. Eichenbaum Director | INFU InfuSystems Holdings, Inc. | Buy | 2,000 | $5.18 | $10.4K Buy | Form 4 ↗ |
| May 19, 2025 | Ronald T. Hundzinski Director | INFU InfuSystems Holdings, Inc. | Buy | 5,000 | $6.09 | $30.4K Buy | Form 4 ↗ |
| May 16, 2025 | Carrie Lachance President and COO, Director | INFU InfuSystems Holdings, Inc. | Buy | 1,967 | $6.10 | $12.0K Buy | Form 4 ↗ |
| May 15, 2025 | Carrie Lachance President and COO, Director | INFU InfuSystems Holdings, Inc. | Buy | 1,165 | $6.01 | $7,002 Buy | Form 4 ↗ |
| May 14, 2025 | Barry G. Steele Executive VP and CFO | INFU InfuSystems Holdings, Inc. | Buy | 3,000 | $5.76 | $17.3K Buy | Form 4 ↗ |
| Nov 27, 2024 | Richard Dilorio Chief Executive Officer, Director | INFU InfuSystems Holdings, Inc. | Sale | 5,398 | $8.87 | $47.9K Sale | Form 4 ↗ |
| Nov 26, 2024 | Richard Dilorio Chief Executive Officer, Director | INFU InfuSystems Holdings, Inc. | Sale | 14,602 | $8.91 | $130.1K Sale | Form 4 ↗ |
| Nov 25, 2024 | Richard Dilorio Chief Executive Officer, Director | INFU InfuSystems Holdings, Inc. | Sale | 20,000 | $9.32 | $186.4K Sale | Form 4 ↗ |
14 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances